Core Viewpoint - Axogen, Inc. has announced an upsized public offering of 4,000,000 shares of common stock priced at $31.00 per share, aiming to raise approximately $124 million before expenses [1][3]. Group 1: Offering Details - The public offering is set to close on January 23, 2026, pending customary closing conditions [2]. - Wells Fargo Securities and Mizuho are the lead book-running managers, with Canaccord Genuity and Raymond James serving as co-managers for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for early payoff and termination of a term loan facility with Oberland Capital, working capital, capital expenditures, and other general corporate purposes [3]. Group 3: Regulatory Information - The offering is made under an automatic shelf registration statement on Form S-3ASR, effective upon filing with the SEC on January 21, 2026 [4]. - A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and available for free on their website [4]. Group 4: Company Overview - Axogen focuses on the development and commercialization of technologies for peripheral nerve repair, aiming to establish nerve repair as the standard of care [6]. - The company's product portfolio includes various nerve repair solutions such as Avance® and Axoguard® products [7].

ALACHUA, Fla. and TAMPA, Fla., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it intends to offer and sell, subject to market and other conditions, $85.0 million of shares of its common stock in a proposed underwritten public offering. In addition, Axogen intends to grant the underwriters a 30-day option to purchase up to an additional $12.75 millio ...

Financial Performance - Q3 2025 revenue increased to $60.1 million, a 23.5% year-over-year growth[11] - Net income for Q3 2025 was $0.7 million, compared to a loss of $1.9 million in Q3 2024[22] - Adjusted EBITDA for Q3 2025 was $9.2 million, with an Adjusted EBITDA margin of 15.4%[22] - Operational cash increased by $3.9 million, reaching $39.8 million as of September 30, 2025[24] Business Growth & Development - High Potential (HiPo) accounts contributed approximately 64% of year-over-year revenue growth[11] - HiPo accounts showed a 19% year-over-year increase in average account productivity[11] - The company trained 62 surgeon pairs in Breast procedures YTD, with 281 procedures performed in Q3, a 20% year-over-year increase[11] - The company trained 57 surgeons in OMF/H&N procedures YTD, exceeding the target of 45[11] - Approximately 1.1 million estimated additional covered lives were added in Q3, with approximately 18.1 million new lives YTD[13] Guidance - The company is raising guidance for the full year 2025, projecting revenue growth of at least 19%, or $222.8 million[26]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Axogen, Inc. and its officers or directors [1] Group 1: Company Developments - On August 25, 2025, Axogen announced that the FDA extended the PDUFA goal date for its Biologics License Application for Avance® Nerve Graft by three months to December 5, 2025 [3] - Following this announcement, Axogen's stock price decreased by $1.47 per share, or 9.04%, closing at $14.79 per share on the same day [3] Group 2: Legal Investigation - Pomerantz LLP is representing investors in investigating claims against Axogen for possible securities fraud or other unlawful business practices [1] - The firm has a long history in corporate, securities, and antitrust class litigation, having recovered numerous multimillion-dollar damages awards for victims of securities fraud [4]